Nov 19, 2019 / 02:45PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks. So my name is Paul Matteis. I'm a biotech analyst at Stifel. Happy to be sitting here with Wade Walke, who's the Vice President of Investor Relations at Ionis. I think we're just going to have Wade kick it off with a 3-minute intro on the company and maybe review recent pipeline and commercial updates on the quarter, and then we can get into Q&A. So Wade, please take it away.
D. Wade Walke - Ionis Pharmaceuticals, Inc. - VP of IR
Thanks, Paul. Thanks for inviting me to the conference. Happy to be here. I'm sure a lot of you know about Ionis Pharmaceuticals. We're the leader in RNA-targeted antisense therapy. We have a large pipeline of more than 40 drugs in development. A lot of those in mid- to late-stage development. This year, we'll have 4 programs in Phase III and I think we have over 10-or-so in Phase II development. So a pretty large pipeline of mid- to late-stage assets.
We've developed
Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Nov 19, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers